Can Covid-19 Affect Your Mitochondria?

Beth talks with Steven Engle, Chief Executive Officer and Director of CohBar, Inc, a biotechnology company developing mitochondria-based therapeutics to treat chronic diseases and extend healthy lifespan. The company’s lead compound, CB4211, is in early stage clinical trial for fatty liver disease and obesity. The company also has four preclinical programs, two in cancer, one in fibrotic diseases, one in type 2 diabetes, and one, which we discuss here, in COVID-19 associated acute respiratory syndrome. You can find more at the company website. The interview starts at about 6 minutes.
Host:Beth Bennett
Executive Producer: Beth Bennett
Show Producer: Beth Bennett
Listen to the show: